Rapid-Acting Insulin Analogues Versus Regular Human Insulin: A Meta-Analysis of Effects on Glycemic Control in Patients with Diabetes

被引:27
|
作者
Nicolucci, Antonio [1 ]
Ceriello, Antonio [2 ,3 ]
Di Bartolo, Paolo [4 ]
Corcos, Antonella [5 ]
Orsini Federici, Marco [5 ]
机构
[1] Ctr Outcomes Res & Clin Epidemiol CORES, Pescara, Italy
[2] Inst Invest Biomed August Pi & Sunyer DIBAPS, Barcelona, Spain
[3] IRCCS MultiMed, Milan, Italy
[4] Internist Ravenna AUSL Romagna, Direttore UO Diabetol, Rete Clin Diabetol Aziendale Dipartimento, Ravenna, Italy
[5] Eli Lilly Italia SpA, Med Affairs Diabet, Sesto Fiorentino, Italy
关键词
Diabetes; Glycemic variability; Meta-analysis; Rapid-acting insulin analogues; Regular human insulin; BLOOD-GLUCOSE CONTROL; HUMAN SOLUBLE INSULIN; HUMAN PREMIX INSULIN; PLASMA-GLUCOSE; NOCTURNAL HYPOGLYCEMIA; INTENSIVE THERAPY; LISPRO INSULIN; NPH INSULIN; TYPE-1; ASPART;
D O I
10.1007/s13300-019-00732-w
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Introduction The aim of this meta-analysis was to investigate the impact of rapid-acting insulin analogues (RAIAs) and regular human insulin (RHI) on glycemic control, including long- and short-term glycemic variability as measured by glycated haemoglobin (HbA1c) and pre- and postprandial glucose (PPG). Methods PubMed was searched for studies published between 1999 and 29 June 2016. Randomised controlled trials of patients with diabetes that assessed the effects of RAIAs or RHI on glycemic control, focusing on preprandial glucose, PPG and HbA1c, were included. Only studies that reported both means and standard deviations for those outcomes were analysed; from these data, weighted mean differences and 95% confidence intervals were generated to yield overall point estimates. The primary outcomes of the meta-analysis were the mean differences between RAIAs and RHI at the end of the study in PPG, preprandial glucose, and HbA1c. Results Twenty-seven studies (n = 7452) were included. The difference in PPG between RAIA- and RHI-treated patients was significant-in favour of RAIAs-in patients with type 1 diabetes (T1D) [- 22.2 mg/dL; 95% confidence interval (CI) - 27.4, - 17.0 mg/dL; P < 0.0001] but not in those with type 2 diabetes (T2D). For preprandial glucose, there was a non-significant trend favouring RHIs in T1D; no data were available for patients with T2D. In patients with T1D, the between-group difference in end-of-treatment (EOT) HbA1c favoured RAIAs (- 0.13%; 95% CI - 0.18, - 0.08%; P < 0.0001), but was not significant in patients with T2D. The main study limitations were the small number and heterogeneity of the included studies. Conclusions These results demonstrate that RAIAs are more effective at reducing PPG and improving HbA1c than RHIs in T1D. More data are required to assess the effect of these agents on glucose control in T2D. Plain Language Summary Plain language summary available for this article.
引用
收藏
页码:573 / 584
页数:12
相关论文
共 50 条
  • [1] Rapid-Acting Insulin Analogues Versus Regular Human Insulin: A Meta-Analysis of Effects on Glycemic Control in Patients with Diabetes
    Antonio Nicolucci
    Antonio Ceriello
    Paolo Di Bartolo
    Antonella Corcos
    Marco Orsini Federici
    Diabetes Therapy, 2020, 11 : 573 - 584
  • [2] Examining the glycaemic and hypoglycaemic benefits with rapid-acting insulin analogues: a meta-analysis of insulin aspart versus regular human insulin in randomised controlled trials
    Heller, S.
    Bode, B. W.
    Kozlovski, P.
    Svendsen, A.
    DIABETOLOGIA, 2009, 52 : S359 - S360
  • [3] Safety of Rapid-Acting Insulin Analogs Versus Regular Human Insulin
    Kitabchi, Abbas E.
    Gosmanov, Aidar R.
    AMERICAN JOURNAL OF THE MEDICAL SCIENCES, 2012, 344 (02): : 136 - 141
  • [4] Regular human insulins versus rapid-acting insulin analogues in children and adolescents with type 1 diabetes: a protocol for a systematic review with meta-analysis and Trial Sequential Analysis
    Petersen, Johanne Juul
    Juul, Sophie
    Kamp, Caroline Barkholt
    Faltermeier, Pascal
    Sillassen, Christina Dam Bjerregaard
    Dos Santos, Tiago Jeronimo
    Jakobsen, Janus Christian
    SYSTEMATIC REVIEWS, 2025, 14 (01)
  • [5] Short acting insulin analogues versus regular human insulin in patients with diabetes mellitus
    Siebenhofer, A.
    Plank, J.
    Berghold, A.
    Jeitler, K.
    Horvath, K.
    Narath, M.
    Gfrerer, R.
    Pieber, T. R.
    COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2006, (02):
  • [6] Effects of rapid-acting insulin analogues insulin glulisine and insulin aspart on postprandial glycemic excursion with single bout of exercise in patients with type 2 diabetes
    Tanaka, Nagaaki
    Hiura, Yoshikazu
    ENDOCRINE JOURNAL, 2015, 62 (05) : 411 - 416
  • [7] Examining the Glycemic and Hypoglycemic Benefits with Rapid-Acting Insulin Analogs: A Meta Analysis of Insulin Aspart vs Regular Human Insulin in Randomized Controlled Trials
    Heller, Simon
    Bode, Bruce W.
    Kozlovski, Plamen
    Svendsen, Anne Louise
    DIABETES, 2009, 58 : A135 - A135
  • [8] Macro- and Microvascular Outcomes in Patients with Type 2 Diabetes Treated with Rapid-Acting Insulin Analogues or Human Regular Insulin: a Retrospective Database Analysis
    Rathmann, W.
    Schloot, N. C.
    Kostev, K.
    Reaney, M.
    Zagar, A. J.
    Haupt, A.
    EXPERIMENTAL AND CLINICAL ENDOCRINOLOGY & DIABETES, 2014, 122 (02) : 92 - 99
  • [9] THREE-YEAR HEALTH CARE EXPENDITURES IN DIABETIC PATIENTS RECEIVING RAPID-ACTING INSULIN ANALOGUES VERSUS THOSE ON HUMAN REGULAR INSULIN
    Cammarota, S.
    Bruzzese, D.
    Catapano, A. L.
    Citarella, A.
    De, Luca L.
    Manzoli, L.
    Masulli, M.
    Menditto, E.
    Mezzetti, A.
    Riegler, S.
    Riccardi, G.
    VALUE IN HEALTH, 2013, 16 (07) : A451 - A451
  • [10] Short-acting insulin analogues vs. regular human insulin in type 2 diabetes: a meta-analysis
    Mannucci, E.
    Monami, M.
    Marchionni, N.
    DIABETES OBESITY & METABOLISM, 2009, 11 (01): : 53 - 59